Abstract A056: A study of race and socioeconomic status impacting therapeutic clinical trial enrollment in adult gliomas patients

Abstract

Abstract Introduction: Under-enrollment in clinical trials significantly limits valid analyses of clinical interventions and generalizability of findings. It can also result in premature study termination, with estimates of 22% to 50% of clinical trials being terminated due to poor accrual. Currently, there are limited reports addressing the influence of race, ethnicity and socioeconomic status on clinical trial enrollment in patients with adult glioma. The goal of this study was to determine if race and socioeconomic status impacts clinical trial participation for glioma patients. Methods: A search within the UCSF Tumor Board Registry identified 852 adult patients discussed over a 2-year period. This cohort was analyzed to determine the rate of therapeutic clinical trial consideration, tumor board recommendation, and study enrollment based on clinical reports available through the electronic medical record. Results: At the time of initial diagnosis, 30.7% and 18.0% of glioma patients were recommended and enrolled in a therapeutic clinical trial, respectively. At the time of recurrence, 38.7% and 25.3% of patient were recommended and enrolled in a clinical trial, respectively. Nineteen percent of the study population belonged to a NIH designated underrepresented minority group, with Asian/Pacific Islander patients comprising 10.3% of the total patient cohort. Percentage of patients who enrolled in a clinical trial was comparable between subgroups. On univariate analysis, only in-state location, distance to the hospital, and WHO grade were associated with consideration, recommendation, and enrollment at initial diagnosis and recurrence. Minority status, insurance type, median household income, and percent below poverty line based on county of residence were not associated with clinical trial recommendation or enrollment. Conclusion: Race and socioeconomic status did not impact clinical trial consideration, tumor board recommendation, or study enrollment. Our results do not support the premise that provider decisions are impacted by biases based on minority or socioeconomic status. Citation Format: Sheantel J Reihl, Ramin A Morshed, Sofia Kakaizada, Eric Zhang, Jacob S Young, Jennifer Clarke, Nicholas Butowski, Jennie Taylor, Nancy Ann Bush, Manish K Aghi, Mitchel S Berger, Susan Chang, Shawn L Hervey-Jumper. A study of race and socioeconomic status impacting therapeutic clinical trial enrollment in adult gliomas patients [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr A056.